September 22, 2011
After winning US approval in May, the new hepatitis C virus treatment telaprevir has been OK'd by EU regulators, Vertex Pharmaceuticals and Johnson & Johnson said Tuesday. J&J has European rights to the drug; Vertex, which holds exclusive US rights, will receive European royalties. The action was anticipated, given that the European Medicines Agency recommended approval in July. Sold under the brand name Incivek in the United States, telaprevir will be branded as Incivo in Europe. In studies, telaprevir administered with standard HCV treatment nearly doubled the cure rate achieved by standard treatment alone.
09.20.2011; Anand Basu
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Post-AIDS 2018 Updates on HIV Cure Research|
|Video SNiP: PET Scan "Hot Spots" Help Visualize Inflammatory Complication of HIV|
|This Week in HIV Research: Many Black MSM on PrEP Are Already Positive|
|HIV-Negative Black Gay Men: Two Recent Studies Show Some Factors That Help Them to Remain So|
|What's Really Behind the Recent Decline in U.S. Hepatitis C Prevalence?|